Literature DB >> 15810992

Resistance to excessive bodyweight gain in risperidone-injected rats.

Miyuki Ota1, Keiji Mori, Akira Nakashima, Yoko S Kaneko, Hisahide Takahashi, Akira Ota.   

Abstract

1. The present study was carried out to explain the resistance of rats injected subcutaneously with risperidone, the atypical antipsychotic drug, for 21 consecutive days at 0.1 mg/kg per day (a dose equivalent to the one used for patients) to result in an excessive bodyweight despite the increase in diet-uptake in rats against risperidone-induced decrease in body temperature. 2. Rectal temperature measurements were made in 8-week-old male Sprague-Dawley rats maintained under standard laboratory conditions using a 12 h daylight cycle. A s.c. injection of risperidone (0.05 mg/kg) produced hypothermia in rats, which was observed during the daily injection for 21 consecutive days. 3. Sera, white and brown adipose tissues, skeletal muscle and liver were extracted from 8-week-old male Sprague-Dawley rats injected subcutaneously with risperidone (0.01 or 0.1 mg/kg per day) or a vehicle for 21 consecutive days. Serum levels of lipids, ketones and thyroid hormone were measured. The mRNA expression levels in these tissues and organs of the genes encoding the substances involved in heat production and/or lipid metabolism were investigated by using quantitative real-time polymerase chain reaction amplification. 4. Serum nonesterified fatty acid levels in risperidone 0.1 mg/kg per day s.c. injected rats were significantly lower than those in vehicle-injected ones. Serum beta-hydroxybutyrate levels in risperidone-injected rats tended to decrease compared with those in vehicle-injected ones. The serum level of neither triiodothyronine nor thyroxine was affected by risperidone s.c. injection at the doses examined, although their values were within normal limits. 5. Risperidone injection (0.1 mg/kg per day) for 21 consecutive days upregulated mRNA expressions in white adipose tissue of uncoupling protein 3 which dissipates energy as heat; peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1alpha which activates mitochondrial biogenesis to expand the oxidative machinery; and PPARalpha which is necessary for the fat-depletion of adipocytes for thermogenesis. The mRNA of lipogenic enzymes (acetyl-CoA carboxylase alpha, fatty-acid synthase and glycerol-3-phosphate acyltransferase), hormone sensitive lipase and beta1-adrenoceptor were also enhanced in white adipose tissue by the injection of 0.1 mg/kg per day risperidone. 6. These findings suggest that the materials for heat generation in white adipose tissue would be readily supplied, which in turn would reduce a storage of lipids in white adipose tissue resulting in the lower rate of bodyweight gain of rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15810992     DOI: 10.1111/j.1440-1681.2005.04184.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

1.  Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice.

Authors:  Megan Beauchemin; Ramaz Geguchadze; Anyonya R Guntur; Kathleen Nevola; Phuong T Le; Deborah Barlow; Megan Rue; Calvin P H Vary; Christine W Lary; Katherine J Motyl; Karen L Houseknecht
Journal:  Pharmacol Res       Date:  2019-12-23       Impact factor: 7.658

2.  A novel insulin sensitizer drug candidate-BGP-15-can prevent metabolic side effects of atypical antipsychotics.

Authors:  Zsuzsanna Literati-Nagy; Kálmán Tory; Botond Literáti-Nagy; Attila Kolonics; László Vígh; László Vígh; József Mandl; Zoltán Szilvássy
Journal:  Pathol Oncol Res       Date:  2012-06-30       Impact factor: 3.201

3.  Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells.

Authors:  Akira Ota; Akira Nakashima; Yoko S Kaneko; Keiji Mori; Hiroshi Nagasaki; Takeshi Takayanagi; Mitsuyasu Itoh; Kazunao Kondo; Toshiharu Nagatsu; Miyuki Ota
Journal:  J Neural Transm (Vienna)       Date:  2012-03-04       Impact factor: 3.575

4.  Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.

Authors:  Katherine J Motyl; Ingrid Dick-de-Paula; Ann E Maloney; Sutada Lotinun; Sheila Bornstein; Francisco J A de Paula; Roland Baron; Karen L Houseknecht; Clifford J Rosen
Journal:  Bone       Date:  2011-08-11       Impact factor: 4.398

5.  Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.

Authors:  Emilie Lauressergues; Françoise Martin; Audrey Helleboid; Emmanuel Bouchaert; Didier Cussac; Régis Bordet; Dean Hum; Gérald Luc; Zouher Majd; Bart Staels; Patrick Duriez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-19       Impact factor: 3.000

6.  Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase.

Authors:  Robert K McNamara; I Jack Magrisso; Rylon Hofacer; Ronald Jandacek; Therese Rider; Patrick Tso; Stephen C Benoit
Journal:  Pharmacol Res       Date:  2012-06-29       Impact factor: 7.658

7.  Risperidone alters food intake, core body temperature, and locomotor activity in mice.

Authors:  Mark B Cope; Xingsheng Li; Patricia Jumbo-Lucioni; Catherine A DiCostanzo; Wendi G Jamison; Robert A Kesterson; David B Allison; Tim R Nagy
Journal:  Physiol Behav       Date:  2008-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.